1033202-32-2 Usage
Uses
Used in Pharmaceutical Industry:
2-((5-Bromo-3-nitropyridin-2-yl)amino)ethanol is used as an intermediate in the synthesis of various pharmaceuticals for its unique chemical properties and reactivity. Its presence of a bromine atom and nitro group allows for further functionalization and modification, making it a versatile building block in the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 2-((5-Bromo-3-nitropyridin-2-yl)amino)ethanol is used as a key intermediate for the preparation of complex organic molecules. Its ability to undergo various chemical reactions, such as nucleophilic substitution, reduction, and coupling, makes it a valuable component in the synthesis of a wide range of organic compounds, including agrochemicals, dyes, and other specialty chemicals.
Used in Research and Development:
2-((5-Bromo-3-nitropyridin-2-yl)amino)ethanol is also utilized in research and development settings for the exploration of new chemical reactions and the study of reaction mechanisms. Its unique structural features provide opportunities for chemists to investigate novel synthetic routes and develop innovative methodologies in organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1033202-32-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,3,2,0 and 2 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1033202-32:
(9*1)+(8*0)+(7*3)+(6*3)+(5*2)+(4*0)+(3*2)+(2*3)+(1*2)=72
72 % 10 = 2
So 1033202-32-2 is a valid CAS Registry Number.
1033202-32-2Relevant academic research and scientific papers
HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF
-
Page/Page column 117, (2010/08/18)
Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
